86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details
臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03489005 (ClinicalTrials.gov) | April 9, 2018 | 29/3/2018 | Effect of BIA 5 1058 on Cardiac Repolarization | A Randomized, Double-blind, Placebo-controlled and Open-label, Active Controlled, 4 Period Crossover Trial to Evaluate the Effect of BIA 5 1058 on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions | Cardiovascular Disease;Pulmonary Arterial Hypertension;Heart Failure | Drug: BIA 5-1058;Drug: Placebo Oral Tablet;Drug: Moxifloxacin 400 mg | Bial - Portela C S.A. | Covance | Completed | 18 Years | 55 Years | All | 49 | Phase 1 | United Kingdom |